AML Induction Therapy – Case

Author: Dr. Sarah Ryan, MD, Queen’s University

Reviewer: Dr. Hassan Sibai, MD, University of Toronto

Upon completion of this case, the learner will be able to:

1. Understand how to make decisions regarding front-line therapy in AML, considering both FLT3 mutated and FLT3 negative cases.

2. Identify common side effects associated with specific AML therapies.

3. Understand how to classify remission status in AML after induction chemotherapy.

Accreditation: This activity is an Accredited Group Learning Activity (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Association of Pathologists (CAP-AC). You may claim a maximum of .25 hours.

The CHS Scientific Planning Committee has planned this case to achieve scientific integrity, objectivity and balance.

Scientific Planning Committee

Dr. Pallavi Ganguli – Resident Physician, Hematology
Dr. Salima Ramdani – Resident Physician, Hematology
Dr. Joanne Britto – Clinical Fellow, Malignant Hematology (Lymphoproliferative Disorders)
Dr. Yan Xu – Fellow Physician, Hematology/Thrombosis
Dr. Siraj Mithoowani – Clinical Hematologist at St. Joseph’s Healthcare, Hamilton
Dr. Hassan Sibai – Assistant Professor of Medicine, Faculty of Medicine, University of Toronto and Staff Physician, Division of Medical Hematology & Oncology, Princess Margaret Cancer Centre

Conflict of Interest: SPC and Author None